HA 130 cartridge for ESRD Patients


Studies have shown that the occurrence of mid- and long term uremic complications in ESRD patients is related to the low clearance rate of middle and large molecule uremic toxins when hemodialysis (HD) alone is adopted.

Low-flux dialysis is the main means of extracorporeal blood purification therapy in developing countries. But it can hardly remove the middle and large molecule uremic toxins and protein-bound toxins; As a result, the patients suffer from long-term complications such as refractory skin itching, mineral bone disorder, refractory hypertension, insomnia, lack of appetite, malnutrition, insulin resistance, cardiovascular complications and poor quality of life.

As the toxic components of uremic toxins and their corresponding biological effects become increasingly clear, blood purification treatment that aims to remove these toxins has developed from a stage of life-sustaining to improving the quality of life.

The adsorbents in the HA130 cartridges are neutral macroporous resin. HA130 selectively adsorb those middle and large molecule uremic toxins (such as parathyroid hormone, ß2-MG, leptin, renin and angiotensin, cytokines, etc.) and protein-bound toxins (such as homocysteine, indole sulfate, spermine, cresol, etc.).

As HA 130 could neither clear excess water in the uremic patient’s body, nor regulate electrolyte and acid base balance, normally it was not advised to be employed alone.

However, when HA130 was combined with HD, the complementary use of the two different methods of blood purification was able to fully remove the metabolites, toxins, and pathogenic factors as well as regulate water, electrolyte, and acid-base balance in patients, rapidly improving the patients’ sleep and appetite while alleviating itchy skin symptoms, which in turn would prevent the recent and long-term complications in patients, improve quality of life, and prolong life.

Simple and convenient operation on any blood purification machine